{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T14:04:06Z","timestamp":1782137046396,"version":"3.54.5"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,3,25]],"date-time":"2025-03-25T00:00:00Z","timestamp":1742860800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,3,25]],"date-time":"2025-03-25T00:00:00Z","timestamp":1742860800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100007052","name":"Memorial Sloan-Kettering Cancer Center","doi-asserted-by":"publisher","award":["P30 CA008748"],"award-info":[{"award-number":["P30 CA008748"]}],"id":[{"id":"10.13039\/100007052","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007052","name":"Memorial Sloan-Kettering Cancer Center","doi-asserted-by":"publisher","award":["P30 CA008748"],"award-info":[{"award-number":["P30 CA008748"]}],"id":[{"id":"10.13039\/100007052","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Nascent Biotech Inc"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-95360-9","type":"journal-article","created":{"date-parts":[[2025,3,25]],"date-time":"2025-03-25T01:56:32Z","timestamp":1742867792000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Characterization of pritumumab in murine models and primate safety study"],"prefix":"10.1038","volume":"15","author":[{"given":"Avani A.","family":"Mody","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajesh","family":"Mukthavaram","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pengfei","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kishore","family":"Gangangari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nagavarakishore","family":"Pillarsetty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pranav R.","family":"Kesari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vijay","family":"Padul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sneha L.","family":"Kesari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elnaz","family":"Rahbarlayegh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark C.","family":"Glassy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Santosh","family":"Kesari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,25]]},"reference":[{"key":"95360_CR1","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1126\/science.1100369","volume":"305","author":"JN Blattman","year":"2004","unstructured":"Blattman, J. N. & Greenberg, P. D. Cancer immunotherapy: A treatment for the masses. Science 305, 200\u2013205. https:\/\/doi.org\/10.1126\/science.1100369 (2004).","journal-title":"Science"},{"key":"95360_CR2","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1126\/science.aaa4971","volume":"348","author":"TN Schumacher","year":"2015","unstructured":"Schumacher, T. N. & Schreiber, R. D. Neoantigens in cancer immunotherapy. Science 348, 69\u201374. https:\/\/doi.org\/10.1126\/science.aaa4971 (2015).","journal-title":"Science"},{"key":"95360_CR3","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.smim.2015.11.002","volume":"28","author":"YC Lu","year":"2016","unstructured":"Lu, Y. C. & Robbins, P. F. Cancer immunotherapy targeting neoantigens. Semin Immunol. 28, 22\u201327 (2016).","journal-title":"Semin Immunol."},{"issue":"10","key":"95360_CR4","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1517\/13543784.3.10.1057","volume":"3","author":"MC Glassy","year":"1994","unstructured":"Glassy, M. C. & McKnight, M. E. Pharming the human lymph node. Expert Opin. Investig. Drugs. 3(10), 1057\u20131060. https:\/\/doi.org\/10.1517\/13543784.3.10.1057 (1994).","journal-title":"Expert Opin. Investig. Drugs"},{"key":"95360_CR5","doi-asserted-by":"publisher","first-page":"5597","DOI":"10.1158\/0008-5472.CAN-16-0431","volume":"76","author":"P Tsou","year":"2016","unstructured":"Tsou, P., Katayama, H., Ostrin, E. J. & Hanash, S. M. The emerging role of B cells in tumor immunity. Cancer Res. 76, 5597\u20135601. https:\/\/doi.org\/10.1158\/0008-5472.CAN-16-0431 (2016).","journal-title":"Cancer Res."},{"key":"95360_CR6","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1007\/978-1-62703-586-6_2","volume":"1060","author":"MC Glassy","year":"2014","unstructured":"Glassy, M. C. & Gupta, R. Technical and ethical limitations in making human monoclonal antibodies (an overview). Methods Mol. Biol. 1060, 9\u201336. https:\/\/doi.org\/10.1007\/978-1-62703-586-6_2 (2014).","journal-title":"Methods Mol. Biol."},{"key":"95360_CR7","doi-asserted-by":"publisher","first-page":"545","DOI":"10.3109\/02841869009090048","volume":"29","author":"GB Challis","year":"1990","unstructured":"Challis, G. B. & Stam, H. J. The spontaneous regression of cancer. A review of cases from 1900 to 1987. Acta Oncol. 29, 545\u2013550. https:\/\/doi.org\/10.3109\/02841869009090048 (1990).","journal-title":"Acta Oncol."},{"key":"95360_CR8","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1007\/s002620100216","volume":"50","author":"U Hobohm","year":"2001","unstructured":"Hobohm, U. Fever and cancer in perspective. Cancer Immunol. Immunother. 50, 391\u2013396. https:\/\/doi.org\/10.1007\/s002620100216 (2001).","journal-title":"Cancer Immunol. Immunother"},{"key":"95360_CR9","doi-asserted-by":"publisher","first-page":"33","DOI":"10.2147\/BTT.S166310","volume":"13","author":"E Cruz","year":"2019","unstructured":"Cruz, E. & Kayser, V. Monoclonal antibody therapy of solid tumors: Clinical limitations and novel strategies to enhance treatment efficacy. Biologics 13, 33\u201351. https:\/\/doi.org\/10.2147\/BTT.S166310 (2019).","journal-title":"Biologics"},{"key":"95360_CR10","doi-asserted-by":"publisher","first-page":"6327","DOI":"10.1073\/pnas.80.20.6327","volume":"80","author":"MC Glassy","year":"1983","unstructured":"Glassy, M. C., Handley, H. H., Hagiwara, H. & Royston, I. UC 729-6, a human lymphoblastoid B-cell line useful for generating antibody-secreting human-human Hybridomas. Proc. Natl. Acad. Sci. USA 80, 6327\u20136331. https:\/\/doi.org\/10.1073\/pnas.80.20.6327 (1983).","journal-title":"Proc. Natl. Acad. Sci. U S A"},{"key":"95360_CR11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1146\/annurev-cellbio-100617-062534","volume":"34","author":"S Etienne-Manneville","year":"2018","unstructured":"Etienne-Manneville, S. Cytoplasmic intermediate filaments in cell biology. Annu. Rev. Cell Dev. Biol. 34, 1\u201328. https:\/\/doi.org\/10.1146\/annurev-cellbio-100617-062534 (2018).","journal-title":"Annu. Rev. Cell Dev. Biol."},{"key":"95360_CR12","doi-asserted-by":"publisher","first-page":"103283","DOI":"10.1016\/j.critrevonc.2021.103283","volume":"160","author":"A Zottel","year":"2021","unstructured":"Zottel, A., Jovcevska, I., Samec, N. & Komel, R. Cytoskeletal proteins as glioblastoma biomarkers and targets for therapy: A systematic review. Crit. Rev. Oncol. Hematol. 160, 103283. https:\/\/doi.org\/10.1016\/j.critrevonc.2021.103283 (2021).","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"95360_CR13","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1177\/117727190600100006","volume":"1","author":"SH Hong","year":"2006","unstructured":"Hong, S. H. et al. Identification of a specific vimentin isoform that induces an antibody response in pancreatic cancer. Biomark. Insights. 1, 175\u2013183 (2006).","journal-title":"Biomark. Insights"},{"key":"95360_CR14","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1016\/j.humimm.2019.03.017","volume":"80","author":"T Divanyan","year":"2019","unstructured":"Divanyan, T., Acosta, E., Patel, D. & Constantino, D. Lopez-Soler, R. I. Anti-vimentin antibodies in transplant and disease. Hum. Immunol. 80, 602\u2013607. https:\/\/doi.org\/10.1016\/j.humimm.2019.03.017 (2019).","journal-title":"Hum. Immunol."},{"key":"95360_CR15","doi-asserted-by":"publisher","unstructured":"Ramos, I., Stamatakis, K. & Oeste, C. L. Perez-Sala, D. Vimentin as a multifaceted player and potential therapeutic target in viral infections. Int. J. Mol. Sci. 21 https:\/\/doi.org\/10.3390\/ijms21134675 (2020).","DOI":"10.3390\/ijms21134675"},{"key":"95360_CR16","doi-asserted-by":"publisher","first-page":"1459","DOI":"10.1016\/j.humimm.2013.06.006","volume":"74","author":"ML Rose","year":"2013","unstructured":"Rose, M. L. Role of anti-vimentin antibodies in allograft rejection. Hum. Immunol. 74, 1459\u20131462. https:\/\/doi.org\/10.1016\/j.humimm.2013.06.006 (2013).","journal-title":"Hum. Immunol."},{"key":"95360_CR17","doi-asserted-by":"publisher","first-page":"77","DOI":"10.3233\/HAB-2001-10204","volume":"10","author":"H Hagiwara","year":"2001","unstructured":"Hagiwara, H., Aotsuka, Y., Yamamoto, Y., Miyahara, J. & Mitoh, Y. Determination of the antigen\/epitope that is recognized by human monoclonal antibody CLN-IgG. Hum. Antibodies 10, 77\u201382 (2001).","journal-title":"Hum. Antibodies"},{"key":"95360_CR18","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1007\/978-1-4939-8958-4_19","volume":"1904","author":"I Babic","year":"2019","unstructured":"Babic, I., Kesari, S. & Glassy, M. C. A binding potency assay for pritumumab and ecto-domain vimentin. Methods Mol. Biol. 1904, 401\u2013415. https:\/\/doi.org\/10.1007\/978-1-4939-8958-4_19 (2019).","journal-title":"Methods Mol. Biol."},{"key":"95360_CR19","doi-asserted-by":"publisher","first-page":"3033","DOI":"10.1007\/s00018-011-0735-1","volume":"68","author":"A Satelli","year":"2011","unstructured":"Satelli, A. & Li, S. Vimentin in cancer and its potential as a molecular target for cancer therapy. Cell. Mol. Life Sci. 68, 3033\u20133046. https:\/\/doi.org\/10.1007\/s00018-011-0735-1 (2011).","journal-title":"Cell. Mol. Life Sci."},{"key":"95360_CR20","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1189\/jlb.0405190","volume":"79","author":"E Moisan","year":"2006","unstructured":"Moisan, E. & Girard, D. Cell surface expression of intermediate filament proteins vimentin and lamin B1 in human neutrophil spontaneous apoptosis. J. Leukoc. Biol. 79, 489\u2013498. https:\/\/doi.org\/10.1189\/jlb.0405190 (2006).","journal-title":"J. Leukoc. Biol."},{"key":"95360_CR21","doi-asserted-by":"publisher","first-page":"72021","DOI":"10.18632\/oncotarget.12458","volume":"7","author":"H Noh","year":"2016","unstructured":"Noh, H. et al. Discovery of cell surface vimentin targeting mAb for direct disruption of GBM tumor initiating cells. Oncotarget 7, 72021\u201372032. https:\/\/doi.org\/10.18632\/oncotarget.12458 (2016).","journal-title":"Oncotarget"},{"key":"95360_CR22","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1016\/j.canlet.2018.07.008","volume":"433","author":"H Noh","year":"2018","unstructured":"Noh, H. et al. Cell surface vimentin-targeted monoclonal antibody 86\u00a0C increases sensitivity to Temozolomide in glioma stem cells. Cancer Lett. 433, 176\u2013185. https:\/\/doi.org\/10.1016\/j.canlet.2018.07.008 (2018).","journal-title":"Cancer Lett."},{"key":"95360_CR23","doi-asserted-by":"publisher","unstructured":"Malickova, K., Janatkova, Ivana, S. & Fucikova, T. Petra and pp. 228\u2013236. (2006). https:\/\/doi.org\/10.2478\/s11536-006-0028-5. Relationship of Anti-vimentin antibodies to anti-endothelial antibodies. Open Medicine vol. 1, 228\u2013236 (2006).","DOI":"10.2478\/s11536-006-0028-5"},{"key":"95360_CR24","doi-asserted-by":"publisher","unstructured":"Nowicki, M. O., Hayes, J. L., Chiocca, E. A. & Lawler, S. E. Proteomic analysis implicates vimentin in glioblastoma cell migration. Cancers (Basel). 11 https:\/\/doi.org\/10.3390\/cancers11040466 (2019).","DOI":"10.3390\/cancers11040466"},{"key":"95360_CR25","doi-asserted-by":"publisher","first-page":"95","DOI":"10.3233\/HAB-170326","volume":"26","author":"I Babic","year":"2018","unstructured":"Babic, I. et al. Pritumumab, the first therapeutic antibody for glioma patients. Hum. Antibodies 26, 95\u2013101. https:\/\/doi.org\/10.3233\/HAB-170326 (2018).","journal-title":"Hum. Antibodies"},{"key":"95360_CR26","first-page":"253","volume":"28","author":"MC Glassy","year":"2020","unstructured":"Glassy, M. C. Unconventional immunotherapy with an unconventional target. Hum. Antibodies 28, 253\u2013258 (2020).","journal-title":"Hum. Antibodies"},{"key":"95360_CR27","doi-asserted-by":"publisher","first-page":"107","DOI":"10.4161\/mabs.3.2.14785","volume":"3","author":"A Beck","year":"2011","unstructured":"Beck, A. & Biosimilar Biobetter and next generation therapeutic antibodies. MAbs 3, 107\u2013110. https:\/\/doi.org\/10.4161\/mabs.3.2.14785 (2011).","journal-title":"MAbs"},{"key":"95360_CR28","unstructured":"Bleck, G. T., Gupta, R. K., Kotlan, B., York, D. & Glassy, M. C. in Proceeding of the 105th Annual Meeting of the American Association for Cancer Research Vol. 74(19 Suppl) (AACR; Cancer Res 2014, San Diego, CA., Apr 5\u20139). (2014)."},{"key":"95360_CR29","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1056\/NEJMra0708126","volume":"359","author":"PY Wen","year":"2008","unstructured":"Wen, P. Y. & Kesari, S. Malignant gliomas in adults. N Engl. J. Med. 359, 492\u2013507. https:\/\/doi.org\/10.1056\/NEJMra0708126 (2008).","journal-title":"N Engl. J. Med."},{"key":"95360_CR30","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1093\/neuonc\/nou087","volume":"16","author":"QT Ostrom","year":"2014","unstructured":"Ostrom, Q. T. et al. The epidemiology of glioma in adults: A state of the science review. Neuro Oncol. 16, 896\u2013913. https:\/\/doi.org\/10.1093\/neuonc\/nou087 (2014).","journal-title":"Neuro Oncol."},{"key":"95360_CR31","doi-asserted-by":"crossref","unstructured":"Nagai, M., Arai, T., Watanabe, K., Ichikawa, K. & Watari, T. Clinical Application of Radiolabeled Human X Human Monoclonal Antibody with Interferon in the Treatment of Malignant Glioma\u2014Preliminary Report  66153\u2013159 (Springer, 1991).","DOI":"10.1007\/978-94-011-3152-0_26"},{"key":"95360_CR32","doi-asserted-by":"publisher","first-page":"127","DOI":"10.3233\/HAB-2009-0209","volume":"18","author":"MC Glassy","year":"2009","unstructured":"Glassy, M. C. & Hagiwara, H. Summary analysis of the pre-clinical and clinical results of brain tumor patients treated with pritumumab. Hum. Antibodies. 18, 127\u2013137. https:\/\/doi.org\/10.3233\/HAB-2009-0209 (2009).","journal-title":"Hum. Antibodies"},{"key":"95360_CR33","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1093\/neuonc\/2.1.45","volume":"2","author":"DR Groothuis","year":"2000","unstructured":"Groothuis, D. R. The blood-brain and blood-tumor barriers: A review of strategies for increasing drug delivery. Neuro Oncol. 2, 45\u201359. https:\/\/doi.org\/10.1093\/neuonc\/2.1.45 (2000).","journal-title":"Neuro Oncol."},{"key":"95360_CR34","unstructured":"Hugwill, A. V. & Glassy, M. C. Idiotypic antibody network regarding malignant cell regression in the brain tumor patients treated with the natural human monoclonal antibody, pritumumab. Integr. Cancer Biol. Res. 1 (2017)."},{"key":"95360_CR35","doi-asserted-by":"publisher","unstructured":"Brentville, V. A. et al. Combination vaccine based on citrullinated vimentin and enolase peptides induces potent CD4-mediated anti-tumor responses. J. Immunother Cancer. 8 https:\/\/doi.org\/10.1136\/jitc-2020-000560 (2020).","DOI":"10.1136\/jitc-2020-000560"},{"key":"95360_CR36","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1517\/14712598.5.10.1333","volume":"5","author":"MC Glassy","year":"2005","unstructured":"Glassy, M. C. & McKnight, M. E. Requirements for human antibody cocktails for oncology. Expert Opin. Biol. Ther. 5, 1333\u20131338. https:\/\/doi.org\/10.1517\/14712598.5.10.1333 (2005).","journal-title":"Expert Opin. Biol. Ther."},{"key":"95360_CR37","unstructured":"Gupta, R. & Glassy, M. C. Oligoclonal and Polyclonal Antibodies in Immunotherapy 2nd ed. edn,  3, 1291\u20131307 (Wiley-VCH Verlag GmbH & Co. KGaA, 2014)."},{"key":"95360_CR38","doi-asserted-by":"publisher","first-page":"3472","DOI":"10.1158\/0008-5472.CAN-08-3886","volume":"69","author":"H Wakimoto","year":"2009","unstructured":"Wakimoto, H. et al. Human glioblastoma-derived cancer stem cells: Establishment of invasive glioma models and treatment with oncolytic herpes simplex virus vectors. Cancer Res. 69, 3472\u20133481. https:\/\/doi.org\/10.1158\/0008-5472.CAN-08-3886 (2009).","journal-title":"Cancer Res."},{"key":"95360_CR39","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1186\/s13550-018-0437-x","volume":"8","author":"C Brand","year":"2018","unstructured":"Brand, C. et al. Leveraging PET to image folate receptor alpha therapy of an antibody-drug conjugate. EJNMMI Res. 8, 87. https:\/\/doi.org\/10.1186\/s13550-018-0437-x (2018).","journal-title":"EJNMMI Res."},{"key":"95360_CR40","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.2967\/jnumed.110.076174","volume":"51","author":"JP Holland","year":"2010","unstructured":"Holland, J. P. et al. 89Zr-DFO-J591 for ImmunoPET of prostate-specific membrane antigen expression in vivo. J. Nucl. Med. 51, 1293\u20131300. https:\/\/doi.org\/10.2967\/jnumed.110.076174 (2010).","journal-title":"J. Nucl. Med."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-95360-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-95360-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-95360-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,25]],"date-time":"2025-03-25T01:56:52Z","timestamp":1742867812000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-95360-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,25]]},"references-count":40,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["95360"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-95360-9","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,25]]},"assertion":[{"value":"5 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"MCG and SK are consultants for and hold equity Nascent Biologics. All the remaining authors declare no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"10178"}}